SEARCH

SEARCH BY CITATION

References

  • 1
    Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998; 30: 295305.
  • 2
    Moore RA. Livial. A review of clinical studies. Br J Obstet Gynaecol 1999; 106(Suppl 19): 121.
  • 3
    Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000; 20: 101107.
  • 4
    Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717712.
  • 5
    Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone. Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 24192422.
  • 6
    Vos RME, Krebbers SFM, Verhoeven CHJ, Delbressine LPC. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002; 30: 106112.
  • 7
    Verhoeven CHJ, Vos RME, Delbressine LPC. The in vivo metabolism of tibolone in animal species. Eur J Metabol Pharmacokinet 2002; 27: 110.
  • 8
    Kloosterboer HJ. Tibolone. A steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76: 231238.
  • 9
    Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of steroidal drugs. J Steroid Biochem Mol Biol 1993; 45: 345351.